Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Veracyte

Veracyte Shows Market Leadership With Jump To 84 RS Rating

A Relative Strength Rating upgrade for Veracyte shows improving technical performance.

Investors Business Daily

Stocks Showing Improving Market Leadership: Veracyte Earns 81 RS Rating

Stocks Showing Improving Market Leadership: Veracyte Earns 81 RS Rating

Veracyte sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Stocks To Watch: Veracyte Sees Relative Strength Rating Rise To 82

Stocks To Watch: Veracyte Sees Relative Strength Rating Rise To 82

A Relative Strength Rating upgrade for Veracyte shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dow Jones Futures Rise; S&P 500 Nears High As Apple Triggers Buy Signal

The Dow and S&P 500 are near all-time highs early Friday as Apple stock flashes a buy signal. Deckers and Atlassian diverged on earnings.

Investors Business Daily

Veracyte Joins Elite List Of Stocks With 95-Plus Composite Rating

On Tuesday, Veracyte got an upgrade for its IBD SmartSelect Composite Rating from 92 to 96.

Investors Business Daily

Navigating 9 Analyst Ratings For Veracyte

9 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Is Veracyte a Smart Bet in Genomic Diagnostics?

Veracyte (VCYT) exceeded Wall Street’s expectations in its first-quarter earnings report and is well-positioned to capitalize on the expanding genomic diagnostics market. However, with its stretched valuation and increased volatility, is VCYT a smart investment? Read on to find out….

inkl

Read news from The Economist, FT, and more,
with one subscription

Veracyte Stock Showing Market Leadership; Earns 93 RS Rating

Veracyte Stock Showing Market Leadership; Earns 93 RS Rating

Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Veracyte Earnings Perspective: Return On Capital Employed

Veracyte Earnings Perspective: Return On Capital Employed

Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million.

Analyst Ratings for Veracyte

Analyst Ratings for Veracyte

Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings:

Recap: Veracyte Q1 Earnings

Recap: Veracyte Q1 Earnings

Veracyte (NASDAQ:VCYT) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by 16.67%, reporting an EPS of $-0.2 versus an estimate of $-0.24.

Preview: Veracyte's Earnings

Preview: Veracyte's Earnings

Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will report an earnings per share (EPS) of $-0.24.

Veracyte's Return On Capital Employed Insights

Veracyte's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, Veracyte (NASDAQ:VCYT) posted sales of $67.34 million. Earnings were up 25.49%, but Veracyte still reported an overall loss of $10.53 million.

Recap: Veracyte Q4 Earnings

Recap: Veracyte Q4 Earnings

Veracyte (NASDAQ:VCYT) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by 6.25%, reporting an EPS of $-0.15 versus an estimate of $-0.16.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

102,755 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

Investor Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play